Posted On: 11/10/2014 9:00:41 PM
Post# of 30067
Re: biotechexpert #10473
We have been repeatedly assured LymPro continues to be on track for Q4 commercialization and revenue generation. Because the share price is at 8 cents and because some analyst makes outlandish predictions for low revenue and massive reverse splits, some investors start to have doubts about LymPro.
I simply don't understand why investors would start having doubts at this point. I wish those with doubts would sell their shares so they could tell the rest of us who remain confident that "we told you so" when the LymPro revenue fails to deliver. I'm confident they will deliver, based on everything I've learned over the last year about the industry needs for this diagnostic test, and what I learned from the data presented at the AD conference back in July.
A single analyst tosses out a seemingly ridiculous low revenue number (based on what?) and this causes investors to start having major concerns and forget all we've learned about the science and the significant need for this test? Not to mention all the testing and work done to get us to the point of commercialization. Does anyone seriously believe the company did no analysis of revenue expectations while working with AD researchers and KOLs before committing to this launch? Do you believe Jason has access to this internal analysis?
Wow! Amazing! Seriously, some here need to stick to mutual fund investing. You don't have the capacity to do critical thinking to assess the reality of a situation.
I'm done here for the evening. Have fun with all of the headless chickens running around the yard.
I simply don't understand why investors would start having doubts at this point. I wish those with doubts would sell their shares so they could tell the rest of us who remain confident that "we told you so" when the LymPro revenue fails to deliver. I'm confident they will deliver, based on everything I've learned over the last year about the industry needs for this diagnostic test, and what I learned from the data presented at the AD conference back in July.
A single analyst tosses out a seemingly ridiculous low revenue number (based on what?) and this causes investors to start having major concerns and forget all we've learned about the science and the significant need for this test? Not to mention all the testing and work done to get us to the point of commercialization. Does anyone seriously believe the company did no analysis of revenue expectations while working with AD researchers and KOLs before committing to this launch? Do you believe Jason has access to this internal analysis?
Wow! Amazing! Seriously, some here need to stick to mutual fund investing. You don't have the capacity to do critical thinking to assess the reality of a situation.
I'm done here for the evening. Have fun with all of the headless chickens running around the yard.
(0)
(0)
